Another-1 Immortalizes Street Art and Streetwear with ‘Drip-Lab’ - combining NFTs, PFPs and NFC Technology
20.7.2023 15:00:00 EEST | Business Wire | Press release
Another-1, the web3 luxury fashion platform, today announces the global launch of Drip-Lab – a multi-faceted phygital NFT project in collaboration with Como-based luxury technical fabric mill Olmetex, and renowned graffiti writer and artist Zoow24.
Drip-Lab launches with a mission to define the global intersection of art, graffiti, technology and streetwear, uniting a new and vibrant community of collectors and connoisseurs in the process. By launching a graffiti and street-culture inspired NFT collection, immortalizing Zoow24’s “The Wall” mural as an NFT, as well as linking the artist’s iconic illustrated characters to an NFC-enabled Olmetex fabricated windbreaker jacket, every aspect of the Drip-Lab project combines to ensure that historically ephemeral street art can be recorded, owned and flexed forever.
At the heart of this project are Zoow24’s five instantly recognisable ‘miniature behemoth’ monster character NFTs - REKT, EXTO, KULT, CRYMELON, and ROOT - which represent vices that can cause an artist to lose their way. The NFTs will be available with over 1,700 backgrounds, 183 monster traits, and 5,555 profile pictures (PFPs) variations as the Drip-Lab community grows.
In short, this unique blend of physical and digital (phygital) utility offers ‘Drip-Lab’ holders around the world the chance to flex a range of digital PFPs, physical products and murals, as well as augmented reality experiences that will be revealed with Another-1’s plans for future activations.
The ‘Drip-Lab’ Roadmap
The Pre-mint for ‘Drip-Lab’ is now live in anticipation of the sale on the Another-1 ADO Launchpad, allowing interested community members exclusive access to mint this project by linking their wallet ahead of the public offering.
Next week, on Wednesday, July 26th at 1pm EDT / 5pm UTC, presale for the project opens, and on July 27th at 1pm EDT / 5pm UTC the public sale will go live. An individual PFP will cost $150 USD each and to forge a customized jacket will cost $350 USD. After the drop, added benefits and utilities will be revealed as holders of these PFP project NFTs will benefit from a free airdrop of an NFT that immortalizes ‘The Wall’ art created by Zoow24 in Como. Adding the fashion and streetwear element, a highly anticipated aspect of this project is a limited edition windbreaker jacket that comes equipped with Near Field Communication (NFC) technology.
Designed by Olmetex, a world-renowned Italian mill setting the standard for fashion’s leading technical fabrics, these jackets showcase five captivating thermo-reactive dual-colorways and feature ZOOW24’s monsters on the inside lining for a customized finish.
Apart from making sure its wearer looks good in the streets, ‘The Writer’s Jacket’ will enable its owners’ to take advantage of Another-1’s ‘Flex-To-Earn’ module and get a 25% cash back airdrop in $AN1 tokens once the collection sales have been concluded, and the NFT redeem for the physical Jacket will be available later this year.
Speaking on the project, artist Zoow24 said, “Drip-Lab is a cautionary expose of what vices become when they spiral out of control. When you stop doing the drugs and the drugs do you. Habits are what make us human and how we choose to spend our time defines us as people.” “As a whole, this collaboration with Another-1 and Olmetex has created an opportunity for me to take my art, my characters and my creativity to a whole range of platforms and possibilities.”
Marco Staglianò, CEO of Another-1, added, “Our mission is to push the envelope and radically change the way art is produced and traded. By establishing the Drip-Lab project along with Olmetex and renowned artists such as Zoow24, we are proving that graffiti is a medium that can live on and be appreciated forever. This is a historical crossover of art, fashion, and groundbreaking technology and we’re excited for what’s still to come.”
“Working with a renowned fabric manufacturer like Olmetex, we also have the opportunity to tie physical fashion to this story of street and digital art. This is a first for the world and we’re excited to see how these passionate communities of street art and streetwear collectors will respond.”
Finally, Olmetex Managing Director, Beatrice Breschi had this to say: “Olmetex has decided to make the facade of its textile company available to graffiti artists, because it has always believed in the close union between fashion and art. This approach is a source of inspiration for our customers, which has always been part of our spirit and characteristics: elasticity, flexibility and constant openness to new ideas and challenges that the market offers. With these NFTs and the physical redemption of the waterproof jacket produced with its own fabrics, Olmetex sets itself the goal of making an art project tangible and fashionable.
“We’re excited to see our near-70 year old Mill involved in a web3 project that creates a new and important way to enjoy art and fashion. We have always been future-focused with our fabric innovation, and now we are taking this mindset to a collaboration that takes fashion, art and fabric into the next decade.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720752001/en/
Contact information
Bridget van Voorst
bridget@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
